Aclarion Launches The Clinical Utility And Economic Trial To Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data

Multiple Physicians and Sites Will Enroll in CLUE in the Coming Months Adding Practical Real-world Data to Aclarion's Expanding Body of Clinical Evidence

BROOMFIELD, CO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the launch of the multi-center CLUE Trial to quantify how often a surgeon changes their original treatment plan once they have access to proprietary Nociscan data. Data from CLUE will provide tremendous insight into the real-world value of adding the Nociscan decision support tool to existing diagnostic evaluation methods for the treatment of chronic low back pain.